FindTrial
Sign In

Study of the effect of tirzepatide on weight and metabolic parameters in patients of Obesity with and without Diabetes mellitus

Efficacy and safety of tirzepatide a twincretin on weight and metabolic parameters in patients of Obesity with and without Diabetes mellitus - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098644
Enrollment
78
Registered
2025-12-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified Health Condition 2: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

Intervention1: Tirzepatide: Patients of obesity will be given tirzepatide 2.5 mg sc which will be escalated up to 10 mg sc as per tolerability Intervention2: Tirzepetide: Patients of obesity with diab

Sponsors

Dr Shruti chandra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient of either gender between ages group 18 to 65 years Individual with BMI more than 25 kg per m square Patient is willing to participate in the study and give written informed consent Patient with or without type 2 DM

Exclusion criteria

Exclusion criteria: Patient having thyroid dysfunction Patients taking concurrent medications known to cause weight gain or weight loss Patient has a history of UTI and recurrent genitourinary infection Patient having renal and hepatic impairment Patient showing intolerance to tirzepatide Pregnant and Lactating women

Design outcomes

Primary

MeasureTime frame
to assess the efficacy of tirzepatide on anthropometric parameters like weight BMI and waist circumferenceTimepoint: zero 6 12 month—

Secondary

MeasureTime frame
To study the demographic profile in patients of Obesity with and without Diabetes mellitusTimepoint: zero month;To assess the efficacy of tirzepatide on glycemic parameters like FBS and HbA1c levels and insulin resistance HOMA IRTimepoint: zero 6 12 month;To assess the efficacy of tirzepatide on lipid profile parameters Serum Cholesterol serum Triglyceride LDLC HDLCTimepoint: zero 6 12 month;To assess the efficacy of tirzepatide on serum transaminase levelTimepoint: zero 6 12 month;to assess the effect of tirzepatide on FIB 4 Score and NFS ScoreTimepoint: zero 6 12 month;To assess the safety of tirzepatide in patients of Obesity with and without Diabetes mellitus as per the patientTimepoint: zero 6 12 month—

Countries

India

Contacts

Public ContactDr Shruti Chandra

MGM Medical college & Hospital

jyobobde@gmail.com09975336706

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026